From the clinical translational point of view, our data strongly suggest that FNTB promoter polymorphisms could be useful for independent prognostic stratification in primary non-metastasized breast cancer patients in order to identify patients with a high risk of recurrence and poor prognosis. Here, FNTB is linked to breast cancer.